Germ cell and nonepithelial ovarian cancer

Berek and Hacker's Gynecologic Oncology: Sixth Edition

Volumn , Issue , 2014, Pages 530-559

  Berek, Jonathan S ^a,b   Friedlander, Michael L ^c,d,e   Hacker, Neville F ^c,e  

^a STANFORD CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e ROYAL HOSPITAL FOR WOMEN   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944094111     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (222)

1. Scully RE, Young RH, Clement RB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. In: Atlas of Tumor Pathology: 3rd series, Fascicle 23. Washington, DC: Armed Forces Institute of Pathology; 1998:169-498.
2. Chen LM, Berek JS. Ovarian and fallopian tubes. In: Haskell CM, ed. Cancer Treatment. 5th ed. Philadelphia, PA: WB Saunders; 2000:900-932.
3. Imai A, Furui T, Tamaya T. Gynecologic tumors and symptoms in childhood and adolescence: 10-years' experience. Int J Gynaecol Obstet. 1994;45:227-234.
4. Gershenson DM. Management of early ovarian cancer: Germ cell and sex-cord stromal tumors. Gynecol Oncol. 1994;55:S62-S72.
5. Gershenson DM. Update on malignant ovarian germ cell tumors. Cancer. 1993;71:1581-1590.
6. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. Eur Urol. 2008;53:478-496.
7. Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. Eur Urol. 2008 Mar;53:497-513.
8. Murugaesu N, Schmid P, Dancey G, et al. Malignant ovarian germ cell tumors: Identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol. 2006;24:4862-4866.
9. Tavassoli FA, Devilee P, eds. Pathology and Genetics of Tumours of the Breast and Female Genital Tract.. Lyon: IARC Press, 2003.
10. Kurman RJ, Scardino PT, McIntire KR, et al. Malignant germ cell tumors of the ovary and testis: An immunohistologic study of 69 cases. Ann Clin Lab Sci. 1979;9:462-466.
11. Obata NH, Nakashima N, Kawai M, et al. Gonadoblastoma with dysgerminoma in one ovary and gonadoblastoma with dysgerminoma and yolk sac tumor in the contralateral ovary in a girl with 46XX karyotype. Gynecol Oncol. 1995;58:124-128.
12. Spanos WJ. Preoperative hormonal therapy of cystic adnexal masses. Am J Obstet Gynecol. 1973;116:551-556.
13. Bremer GL, Land JA, Tiebosch A, et al. Five different histologic subtypes of germ cell malignancies in an XY female. Gynecol Oncol. 1993;50:247-248.
14. Mayordomo JI, Paz-Ares L, Rivera F, et al. Ovarian and extragonadal malignant germ-cell tumors in females: A single-institution experience with 43 patients. Ann Oncol. 1994;5:225-231.
15. Rabban JT, Zaloudek CJ. A practical approach to immunohistochemical diagnosis of ovarian germ cell tumours and sex cord-stromal tumours. Histopathology. 2013;62:71-88.
16. Piura B, Dgani R, Zalel Y, et al. Malignant germ cell tumors of the ovary: A study of 20 cases. J Surg Oncol 1995;59:155-161.
17. Solheim O, Kaern J, Trope CG, et al. Malignant ovarian germ cell tumors: Presentation, survival and second cancer in a population based Norwegian cohort (1953-2009). Gynecol Oncol. 2013;131(2):330-335.
18. Lu KH, Gershenson DM. Update on the management of ovarian germ cell tumors. J Reprod Med. 2005;50:417-425.
19. Gordon A, Lipton D, Woodruff JD. Dysgerminoma: A review of 158 cases from the Emil Novak Ovarian Tumor Registry. Obstet Gynecol. 1981;58:497-504.
20. Thomas GM, Dembo AJ, Hacker NF, et al. Current therapy for dysgerminoma of the ovary. Obstet Gynecol 1987;70:268-275.
21. Low JJ, Perrin LC, Crandon AJ, et al. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors: A review of 74 cases. Cancer. 2000;89:391-398.
22. Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med. 1987;316:1435-1440.
23. Mangili G, Sigismondi C, Lorusso D, et al. Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience. Gynecol Oncol. 2011;121:280-284.
24. Patterson DM, Murugaesu N, Holden L, et al. A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. Int J Gynecol Cancer. 2008;18(1):43-50. PMID:17466047.
25. Williams SD, Blessing JA, Hatch K, et al. Chemotherapy of advanced ovarian dysgerminoma: Trials of the Gynecologic Oncology Group. J Clin Oncol. 1991;9:1950-1955.
26. Williams SD, Blessing JA, Moore DH, et al. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. Ann Intern Med. 1989;111:22-27.
27. Williams SD, Blessing JA, Liao S, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: A trial of the Gynecologic Oncology Group. J Clin Oncol. 1994;12:701-706.
28. Gershenson DM, Morris M, Cangir A, et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol. 1990;8:715-720.
29. Bekaii-Saab T, Einhorn LH, Williams SD. Late relapse of ovarian dysgerminoma: Case report and literature review. Gynecol Oncol. 1999;72:111-112.
30. Kurtz JE, Jaeck D, Maloisel F, et al. Combined modality treatment for malignant transformation of a benign ovarian teratoma. Gynecol Oncol. 1999;73:319-321.
31. Williams SD. Ovarian germ cell tumors: An update. Semin Oncol. 1998;25:407-413.
32. Pawinski A, Favalli G, Ploch E, et al. PVB chemotherapy in patients with recurrent or advanced dysgerminoma: A phase II study of the EORTC Gynaecological Cancer Cooperative Group. Clin Oncol (R Coll Radiol). 1998;10:301-305.
33. Rogers PC, Olson TA, Cullen JW, et al. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study-Pediatric Oncology Group 9048 and Children's Cancer Group 8891. J Clin Oncol. 2004; 22:3563-3569.
34. Brewer M, Gershenson DM, Herzog CE, et al. Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol. 1999;17:2670-2675.
35. Gershenson DM. Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol. 1988;6:270-275.
36. Kanazawa K, Suzuki T, Sakumoto K. Treatment of malignant ovarian germ cell tumors with preservation of fertility: Reproductive performance after persistent remission. Am J Clin Oncol. 2000;23:244-248.
37. El-Lamie IK, Shehata NA, Abou-Loz SK, et al. Conservative surgical management of malignant ovarian germ cell tumors: The experience of the Gynecologic Oncology Unit at Ain Shams University. Eur J Gynaecol Oncol. 2000;21:605-609.
38. Tangir J, Zelterman D, Ma W, et al. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol. 2003;101:251-257.
39. Loehrer PJ, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995;13:470-476.
40. Bajorin DF, Sarosdy MF, Pfister GD, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multi-institutional study. J Clin Oncol. 1993;11:598-606.
41. Schwartz PE, Chambers SK, Chambers JT, et al. Ovarian germ cell malignancies: The Yale University experience. Gynecol Oncol. 1992;45:26-31.
42. Williams SD, Blessing JA, DiSaia PJ, et al. Second-look laparotomy in ovarian germ cell tumors. Gynecol Oncol. 1994;52:287-291.
43. Culine S, Lhomme C, Michel G, et al. Is there a role for second-look laparotomy in the management of malignant germ cell tumors of the ovary? Experience at Institute Gustave Roussy. J Surg Oncol. 1996;62:40-45.
44. De Santis M, Bokemeyer C, Becherer A, et al. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma. J Clin Oncol. 2001;19:3740-3744.
45. Siekiera J, Małkowski B, Jóźwicki W, et al. Can we rely on PET in the follow-up of advanced seminoma patients? Urol Int. 2012;88(4):405-409
46. Motzer RJ, Sheinfeld J, Mazumdar M, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol. 2000;18:2413-2418.
47. Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol. 2005;16:1152-1159.
48. Feldman D, Huddart R, Hall E, et al. Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER trial. J Cancer. 2011;2:374-377.
49. Han JY, Nava-Ocampo AA, Kim TJ, et al. Pregnancy outcome after prenatal exposure to bleomycin, etoposide and cisplatin for malignant ovarian germ cell tumors: Report of 2 cases. Reprod Toxicol. 2005;19(4):557-561.
50. Elit L, Bocking A, Kenyon C, et al. An endodermal sinus tumor diagnosed in pregnancy: Case report and review of the literature. Gynecol Oncol. 1999;72:123-127
51. Kumar S, Shah JP, Bryant CS, et al. The prevalence and prognostic impact of lymph node metastases in malignant germ cell tumors of the ovary. Gynecol Oncol. 2008;110:125-132.
52. Mahdi H, Swensen RE, Hanna R, et al. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. Br J Cancer. 2011;105(4):493-497.
53. O'Conner DM, Norris HJ. The influence of grade on the outcome of stage I ovarian immature (malignant) teratomas and the reproducibility of grading. Int J Gynecol Pathol. 1994;13:283-289.
54. Norris HJ, Zirkin HJ, Benson WL. Immature (malignant) teratoma of the ovary: A clinical and pathologic study of 58 cases. Cancer. 1976;37:2359-2372.
55. Ulbright TM. Germ cell tumors of the gonads: A selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. A review. Mod Pathol. 2005;18(suppl 2):S61-S79.
56. Heifetz SA, Cushing B, Giller R, et al. Immature teratomas in children: Pathologic considerations: A report from the combined Pediatric Oncology Group/Children's Cancer Group. Am J Surg Pathol. 1998;22:1115-1124.
57. Marina NM, Cushing B, Giller R, et al. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study. J Clin Oncol. 1999;17:2137-2143.
58. Ferguson AW, Katabuchi H, Ronnett BM, et al. Glial implants in gliomatosis peritonei arise from normal tissue, not from the associated teratoma. Am J Pathol. 2001;159:51-55.
59. Best DH, Butz GM, Moller K, et al. Molecular analysis of an immature ovarian teratoma with gliomatosis peritonei and recurrence suggests genetic independence of multiple tumors. Int J Oncol. 2004;25:17-25.
60. Dimopoulos MA, Papadopoulou M, Andreopoulou E, et al. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: A Hellenic Cooperative Oncology Group study. Gynecol Oncol. 1998;70:70-74.
61. Bafna UD, Umadevi K, Kumaran C, et al. Germ cell tumors of the ovary: Is there a role for aggressive cytoreductive surgery for nondysgerminomatous tumors? Int J Gynecol Cancer. 2001;11:300-304.
62. De Palo G, Zambetli M, Pilotti S, et al. Non-dysgerminomatous tumors of the ovary treated with cisplatin, vinblastine, and bleomycin: Long-term results. Gynecol Oncol. 1992;47:239-246.
63. Culine S, Kattan J, Lhomme C, et al. A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant non-dysgerminomatous germ-cell tumors of the ovary. Gynecol Oncol. 1994;54:47-53.
64. Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: Carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. J Clin Oncol. 2000;18:3809-3818.
65. Cushing B, Giller R, Cullen JW, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: A pediatric intergroup study-Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol. 2004;22:2691-2700.
66. Lopes LF, Macedo CR, Pontes EM, et al. Cisplatin and etoposide in childhood germ cell tumor: Brazilian pediatric oncology society protocol GCT-91. J Clin Oncol. 2009;27:1297-1303.
67. Mangili G, Scarfone G, Gadducci A, et al. Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). Gynecol Oncol. 2010;119:48-52.
68. Segelov E, Campbell J, Ng M, et al. Cisplatin-based chemotherapy for ovarian germ cell malignancies: The Australian experience. J Clin Oncol. 1994;12:378-384.
69. Bonazzi C, Peccatori F, Colombo N, et al. Pure ovarian immature teratoma, a unique and curable disease: 10 years' experience of 32 prospectively treated patients. Obstet Gynecol. 1994;84:598-604.
70. Cangir A, Smith J, van Eys J. Improved prognosis in children with ovarian cancers following modified VAC (vincristine sulfate, dactinomycin, and cyclophosphamide) chemotherapy. Cancer. 1978;42:1234-1238.
71. Chapman DC, Grover R, Schwartz PE. Conservative management of an ovarian polyembryoma. Obstet Gynecol. 1994;83:879-882.
72. Slayton RE, Park RC, Silverberg SC, et al. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary: A Gynecologic Oncology Group study (a final report). Cancer. 1985;56:243-248.
73. Creasman WJ, Soper JT. Assessment of the contemporary management of germ cell malignancies of the ovary. Am J Obstet Gynecol. 1985;153:828-834.
74. Taylor MH, DePetrillo AD, Turner AR. Vinblastine, bleomycin, and cisplatin in malignant germ cell tumors of the ovary. Cancer. 1985;56:1341-1349.
75. Culine S, Lhomme C, Kattan J, et al. Cisplatin-based chemotherapy in the management of germ cell tumors of the ovary: The Institute Gustave Roussy experience. Gynecol Oncol. 1997;64:160-165.
76. Williams SD, Wong LC, Ngan HYS. Management of ovarian germ cell tumors. In: Gershenson DM, McGuire WP, eds. Ovarian Cancer. New York, NY: Churchill-Livingstone; 1998:399-415.
77. Bokemeyer C, Köhrmann O, Tischler J, et al. Schmoll HJA randomized trial of cisplatin, etoposide, and bleomycin (PEB) versus carboplatin, etoposide, and bleomycin (CEB) for patients with "good-risk" metastatic non-seminomatous germ cell tumors. Ann Oncol. 1996;7:1015-1021.
78. Horwich A, Sleijfer DT, Fosså SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol. 1997;15:1844-1852.
79. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J. Clin Oncol. 2001;19(6):1629-1640. PMID:11250991.
80. Abdul Razak AR, Li L, Bryant A, et al. Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease. Cochrane Database Syst Rev. 2011;(3):CD007584. doi:10.1002/14651858.CD007584.pub2.
81. Fizazi K, Pagliaro LC, Flechon A, et al. A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ cell tumors: Results of GETUG 13. 2013 ASCO Annual Meeting. Abstract LBA4500.
82. Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: A phase II study. Ann Oncol. 2004;15(3):493-497. PMID:14998855.
83. Einhorn LH, Brames MJ, Juliar B, et al. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol. 2007;25(5):513-516. PMID:17290059.
84. Theodore C, Chevreau C, Yataqhene Y, et al. A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors. Ann Oncol. 2008;9(8):1465-1469. PMID:18385203.
85. Shiraishi T, Nakamura T, Mikami K, et al. Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors. Int J Clin Oncol. 2009;14(5):436-441. PMID:19856053.
86. Li J, Yang W, Wu X. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: A study in Chinese patients. Gynecol Oncol. 2007;105:769-775.
87. Rezk Y, Sheinfeld J, Chi DS. Prolonged survival following salvage surgery for chemorefractory ovarian immature teratoma: A case report and review of the literature. Gynecol Oncol. 2005;96:883.
88. Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357(4):340-348. PMID:17652649.
89. Voigt W, Kegel T, Maher G, et al. Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer. Ann. Oncol. 2006; 17(3):531-533. PMID:16234294.
90. Hariprasad R, Kumar L, Janga D, et al. Growing teratoma syndrome of ovary. Int J Clin Oncol. 2008;13:83-87.
91. Tangjitgamol S, Manusirivithaya S, Leelahakorn S, et al. The growing teratoma syndrome: A case report and a review of the literature. Int J Gynecol Cancer. 2006;16(suppl 1):384-390.
92. Mego M, Reckova M, Sycova-Mila Z, et al. Bevacizumab in a growing teratoma syndrome. Case report. Ann. Oncol. 2007;18(5):962-963. PMID:17434900.
93. Carver BS, Shayegan B, Serio A, et al. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol. 2007;25:1033-1037.
94. Mathew GK, Singh SS, Swaminathan RG, et al. Laparotomy for post chemotherapy residue in ovarian germ cell tumors. J Postgrad Med. 2006;52:262-265.
95. Billmire D, Vinocur C, Rescorla F, et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: An intergroup study. J Pediatr Surg. 2004;39(3):424-429. PMID:15017564.
96. Lai CH, Chang TC, Hsueh S, et al. Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol. 2005;96:784-791.
97. Talerman A. Germ cell tumors of the ovary. Curr Opin Obstet Gynecol. 1997;9:44-47.
98. Kleiman GM, Young RH, Scully RE. Primary neuroectodermal tumors of the ovary: A report of 25 cases. Am J Surg Pathol. 1993; 17:764-778.
99. Sasaki H, Furusata M, Teshima S, et al. Prognostic significance of histopathological subtypes in stage I pure yolk sac tumour of the ovary. Br J Cancer. 1994;69:529-536.
100. Fujita M, Inoue M, Tanizawa O, et al. Retrospective review of 41 patients with endodermal sinus tumor of the ovary. Int J Gynecol Cancer. 1993;3:329-335.
101. de La Motte Rouge T, Pautier P, et al. Prognostic factors in women treated for ovarian yolk sac tumour: A retrospective analysis of 84 cases. Eur. J. Cancer. 2011. PMID:20851596.
102. Kawai M, Kano T, Kikkawa F, et al. Seven tumor markers in benign and malignant germ cell tumors of the ovary. Gynecol Oncol. 1992;45:248-253.
103. Abu-Rustum NR, Aghajanian C. Management of malignant germ cell tumors of the ovary. Semin Oncol. 1998;25:235-242.
104. Newlands ES, Southall PJ, Paradinas FJ, et al. Management of ovarian germ cell tumours. In: Williams CJ, Krikorian JG, Green MR, et al., eds. Textbook of Uncommon Cancer. New York, NY: John Wiley & Sons; 1988:37-53.
105. Ueda G, Abe Y, Yoshida M, et al. Embryonal carcinoma of the ovary: A six-year survival. Gynecol Oncol. 1990;31:287-292.
106. Kammerer-Doak D, Baurick K, Black W, et al. Endodermal sinus tumor and embryonal carcinoma of the ovary in a 53-year-old woman. Gynecol Oncol. 1996;63:133-137.
107. Tay SK, Tan LK. Experience of a 2-day BEP regimen in postsurgical adjuvant chemotherapy of ovarian germ cell tumors. Int J Gynecol Cancer. 2000;10:13-18.
108. Haugnes HS, Aass N, Fosså SD, et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol. 2009;27:2779-2786.
109. Talukdar S, Kumar S, Bhatla N, et al. Neo-adjuvant chemotherapy in the treatment of advanced malignant germ cell tumors of ovary. Gynecol Oncol. 2014;132(1):28-32. pii: S0090-8258(13)01254-7.
110. Simosek T, Trak B, Thnoc M, et al. Primary pure choriocarcinoma of the ovary in reproductive ages: A case report. Eur J Gynaecol Oncol. 1998;19:284-286.
111. Oliva E, Andrada E, Pezzica E, et al. Ovarian carcinomas with choriocarcinomatous differentiation. Cancer. 1993;72:2441-2446.
112. Kong B, Tian YJ, Zhu WW, et al. A pure nongestational ovarian choriocarcinoma in a 10-year-old girl: Case report and literature review. J Obstet Gynaecol Res. 2009;35(3):574-578. PMID:19527404.
113. Cushing B, Giller R, Ablin A, et al. Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: A report of the Pediatric Oncology Group and the Children's Cancer Group. Am J Obstet Gynecol. 1999;181:353-358.
114. Dark GG, Bower M, Newlands ES, et al. Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol. 1997;15:620-624.
115. Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw. 2006;4:1059-1070.
116. Chaudhary UB, Haldas JR. Long-term complications of chemotherapy for germ cell tumours. Drugs. 2003;63:1565-1577.
117. Matei D, Miller AM, Monahan P, et al. Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: A Gynecologic Oncology Group study. J Clin Oncol. 2009; 27:4142-4149.
118. Gershenson DM, Miller AM, Champion VL, et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: A Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:2792-2797.
119. Zhang R, Sun YC, Zhang GY, et al. Treatment of malignant germ cell tumors and preservation of fertility. Eur J Gynaecol Oncol. 2012; 33:489-492.
120. Monahan PO, Champion VL, Zhao Q, et al. Case-control comparison of quality of life in long-term ovarian germ cell tumor survivors: A gynecologic oncology group study. J Psychosoc Oncol. 2008; 26(3):19-42. PMID:19042263.
121. Schneider DT, Hilgenfeld E, Schwabe D, et al. Acute myelogenous leukemia after treatment for malignant germ cell tumors in children. J Clin Oncol. 1999;17:3226-3233.
122. Kollmannsberger C, Beyer J, Droz JP, et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol. 1998;16:3386-3391.
123. Young RE, Scully RE. Ovarian sex cord-stromal tumors: Problems in differential diagnosis. Ann Pathol. 1988;23:237-296.
124. Miller BE, Barron BA, Wan JY, et al. Prognostic factors in adult granulosa cell tumor of the ovary. Cancer. 1997;79:1951-1955.
125. Boyce EA, Costaggini I, Vitonis A, et al. The epidemiology of ovarian granulosa cell tumors: A case-control study. Gynecol Oncol. 2009;115:221-225.
126. Malmström H, Högberg T, Risberg B, et al. Granulosa cell tumors of the ovary: Prognostic factors and outcome. Gynecol Oncol. 1994; 52:50-55.
127. Segal R, DePetrillo AD, Thomas G. Clinical review of adult granulosa cell tumors of the ovary. Gynecol Oncol. 1995;56:338-344.
128. Cronje HS, Niemand I, Barn, RH, et al. Review of the granulosa-theca cell tumors from the Emil Novak ovarian tumor registry. Am J Obstet Gynecol. 1999;180:323-328.
129. Roth LM. Recent advances in the pathology and classification of ovarian sex cord-stromal tumors. Internat J Gynecol Pathol. 2006:25:199-215.
130. Aboud E. A review of granulosa cell tumours and thecomas of the ovary. Arch Gynecol Obstet. 1997;259:161-165.
131. Chechia A, Attia L, Temime RB, et al. Incidence, clinical analysis, and management of ovarian fibromas and fibrothecomas. Am J Obstet Gynecol. 2008;199:473.e1-e4.
132. Young R, Clement PB, Scully RE. The ovary. In: Sternberg SS, ed. Diagnostic Surgical Pathology. New York, NY: Raven Press, 1989:1687.
133. Zhao C, Vinh TN, McManus K, et al. Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. Am J Surg Pathol. 2009; 33:354-366.
134. Shah SP, Köbel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009;360:2719-2729.
135. Köbel M, Gilks CB, Huntsman DG. Adult-type granulosa cell tumors and FOXL2 mutation. Cancer Res. 2009;69:9160-9162.
136. Lappohn RE, Burger HG, Bouma J, et al. Inhibin as a marker for granulosa-cell tumors. N Engl J Med. 1989;321:790-793.
137. Hildebrandt RH, Rouse RV, Longacre TA. Value of inhibin in the identification of granulosa cell tumors of the ovary. Hum Pathol. 1997;28:1387-1395.
138. Richi M, Howard LN, Bratthauae GL, et al. Use of monoclonal antibody against human inhibin as a marker for sex-cord-stromal tumors of the ovary. Am J Surg Pathol. 1997;21:583-589.
139. Mom CH, Engelen MJ, Willemse PH, et al. Granulosa cell tumors of the ovary: The clinical value of serum inhibin A and B levels in a large single center cohort. Gynecol Oncol. 2007;105:365-372.
140. Matias-Guiu X, Pons C, Prat J. Müllerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors. Hum Pathol. 1998;29:840-845.
141. McCluggage WG. Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms. J Clin Pathol. 2000;53:327-334.
142. Rey RA, Lhomme C, Marcillac I, et al. Antimüllerian hormone as a serum marker of granulosa cell tumors of the ovary: Comparative study with serum alpha-inhibin and estradiol. Am J Obstet Gynecol. 1996;174:958-965.
143. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003;21:1180-1189.
144. Chang HL, Pahlavan N, Halpern EF, et al. Serum Müllerian Inhibiting Substance/anti-Müllerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology. Gynecol Oncol. 2009;114:57-60.
145. Geerts I, Vergote I, Neven P, et al. The role of inhibins B and antimüllerian hormone for diagnosis and follow-up of granulosa cell tumors. Int J Gynecol Cancer. 2009;19(5):847-855.
146. Kommoss S, Gilks CB, Penzel R, et al. A current perspective on the pathological assessment of FOXL2 in adult-type granulosa cell tumours of the ovary. Histopathology. 2014;64(3):380-388.
147. Brown J, Sood AK, Deavers MT, et al. Patterns of metastasis in sex cord-stromal tumors of the ovary: Can routine staging lymphadenectomy be omitted? Gynecol Oncol. 2009;113:86-90.
148. Abu-Rustum NR, Restivo A, Ivy J, et al. Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. Gynecol Oncol. 2006;103:31-34.
149. National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2013).
150. Wolf JK, Mullen J, Eifel PJ, et al. Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. Gynecol Oncol. 1999;73:35-41.
151. Savage P, Constenla D, Fisher C, et al. Granulosa cell tumours of the ovary: Demographics, survival and the management of advanced disease. Clin Oncol (R Coll Radiol). 1998;10:242-245.
152. Gershenson DM, Copeland IA, Kavanagh JJ, et al. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide. Obstet Gynecol. 1987;5:765-769.
153. Holland DR, Le Riche J, Swenerton KD, et al. Flow cytometric assessment of DNA ploidy is a useful prognostic factor for patients with granulosa cell ovarian tumors. Int J Gynecol Cancer. 1991;1:227-232.
154. Uygun K, Aydiner A, Saip P, et al. Clinical parameters and treatment results in recurrent granulosa cell tumor of the ovary. Gynecol Oncol. 2003;88:400-403.
155. Al-Badawi IA, Brasher PM, Ghatage P, et al. Postoperative chemotherapy in advanced ovarian granulosa cell tumors. Int J Gynecol Cancer. 2002;12:119-123.
156. Homesley HD, Bundy BN, Hurteau JA, et al. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. Gynecol Oncol. 1999;72:131-137.
157. Colombo N, Sessa C, Landoni F, et al. Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary. Obstet Gynecol. 1986;67:265-268.
158. Zambetti M, Escobedo A, Pilotti S, et al. Cis-platinum/vinblastine/bleomycin combination chemotherapy in advanced or recurrent granulosa cell tumors of the ovary. Gynecol Oncol. 1990;36:317-320.
159. Lauszus FF, Petersen, AC, Greisen J, et al. Granulosa cell tumor of the ovary: A population-based study of 37 women with stage I disease. Gynecol Oncol. 2001;81:456-460.
160. Gershenson DM, Morris M, Burke TW, et al. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Obstet Gynecol. 1996;87:527-531.
161. Powell JL, Otis CN. Management of advanced juvenile granulosa cell tumor of the ovary. Gynecol Oncol. 1997;64:282-284.
162. Pecorelli S, Wagenaar HC, Vergote IB, et al. Cisplatin (P), vinblastine (V), and bleomycin (B) combination chemotherapy in recurrent or advanced granulosa(-theca) cell tumours of the ovary. An EORTC Gynaecological Cancer Cooperative Group study. Eur J Cancer. 1999;35:1331-1337.
163. Muntz HG, Goff BA, Fuller AF Jr. Recurrent ovarian granulosa cell tumor: Role of combination chemotherapy with report of a long-term response to a cyclophosphamide, doxorubicin, and cisplatin regimen. Eur J Gynaecol Oncol. 1990;11:263-268.
164. Tao X, Sood AK, Deavers MT, et al. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol. 2009;114(3):431-436.
165. Tresukosol D, Kudelka AP, Edwards CL, et al. Recurrent ovarian granulosa cell tumor: A case report of a dramatic response to Taxol. Int J Gynecol Cancer. 1995;5:156-159.
166. Brown J, Shvartsman HS, Deavers MT, et al. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol. 2004; 22:3517.
167. Brown J, Shvartsman HS, Deavers MT, et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol. 2005; 97:489-496.
168. Hardy RD, Bell JG, Nicely CJ, et al. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: Case report and review of the literature. Gynecol Oncol. 2005;96:865-869.
169. Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod. 1994;9:1364-1379.
170. Martikainen H, Penttinen J, Huhtaniemi I, et al. Gonadotropin-releasing hormone agonist analog therapy effective in ovarian granulosa cell malignancy. Gynecol Oncol. 1989;35:406-408.
171. Fishman A, Kudelka AP, Tresukosol D, et al. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J Reprod Med. 1996;41:393-396.
172. Briasoulis E, Karavasilis V, Pavlidis N. Megestrol activity in recurrent adult type granulosa cell tumour of the ovary. Ann Oncol. 1997; 8:811-812.
173. Freeman SA, Modesitt SC. Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: A report of 2 cases. Gynecol Oncol. 2006;103:755-758.
174. Sommeijer DW, Sjoquist KM, Friedlander M. Hormonal treatment in recurrent and metastatic gynaecological cancers: A review of the current literature. Curr Oncol Rep. 2013;15(6):541-548.
175. Lee YK, Park NH, Kim JW, et al. Characteristics of recurrence in adult-type granulosa cell tumor. Int J Gynecol Cancer. 2008;18:642-647.
176. Zhang M, Cheung MK, Shin JY, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary-an analysis of 376 women. Gynecol Oncol. 2007;104:396-400.
177. Chan JK, Zhang M, Kaleb V, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary-a multivariate analysis. Gynecol Oncol. 2005;96:204.
178. Auranen A, Sundström J, Ijäs J, et al. Prognostic factors of ovarian granulosa cell tumor: A study of 35 patients and review of the literature. Int J Gynecol Cancer. 2007;17:1011-1018.
179. Ala-Fossi SL, Maenpaa J, Aine R, et al. Prognostic significance of p53 expression in ovarian granulosa cell tumors. Gynecol Oncol. 1997;66:475-479.
180. Roth LM, Anderson MC, Govan AD, et al. Sertoli-Leydig cell tumors: A clinicopathologic study of 34 cases. Cancer. 1981;48:187-197.
181. Tomlinson MW, Treadwell MC, Deppe G. Platinum based chemotherapy to treat recurrent Sertoli-Leydig cell ovarian carcinoma during pregnancy. Eur J Gynaecol Oncol. 1997;18:44-46.
182. Le T, Krepart GV, Lotocki RJ, et al. Malignant mixed mesodermal ovarian tumor treatment and prognosis: A 20-year experience. Gynecol Oncol. 1997;65:237-240.
183. Piura B, Rabinovich A, Yanai-Inbar I, et al. Primary sarcoma of the ovary: Report of five cases and review of the literature. Eur J Gynaecol Oncol. 1998;19:257-261.
184. Topuz E, Eralp Y, Aydiner A, et al. The role of chemotherapy in malignant mixed müllerian tumors of the female genital tract. Eur J Gynaecol Oncol. 2001;22:469-472.
185. van Rijswijk RE, Tognon G, Burger CW, et al. The effect of chemotherapy on the different components of advanced carcinosarcomas (malignant mixed mesodermal tumors) of the female genital tract. Int J Gynecol Cancer. 1994;4:52-60.
186. Berek JS, Hacker NF. Sarcomas of the female genital tract. In: Eilber FR, Morton DL, Sondak VK, et al., eds. The soft tissue sarcomas. Orlando, FL: Grune & Stratton; 1987:229-238.
187. Barakat RR, Rubin SC, Wong G, et al. Mixed mesodermal tumor of the ovary: Analysis of prognostic factors in 31 cases. Obstet Gynecol. 1992;80:660-664.
188. Fowler JM, Nathan L, Nieberg RK, et al. Mixed mesodermal sarcoma of the ovary in a young patient. Eur J Obstet Gynecol Reprod Biol. 1996;65:249-253.
189. Silasi DA, Illuzzi JL, Kelly MG, et al. Carcinosarcoma of the ovary. Int J Gynecol Cancer. 2008;18:22-29.
190. Leiser AL, Chi DS, Ishill NM, et al. Carcinosarcoma of the ovary treated with platinum and taxane: The Memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol. 2007;105:657-661.
191. Young RH, Oliva E, Scully RE. Small cell sarcoma of the ovary, hypercalcemic type: A clinicopathological analysis of 150 cases. Am J Surg Pathol. 1994;18:1102-1116.
192. Harrison ML, Hoskins P, du Bois A, et al. Small cell of the ovary, hypercalcemic type-analysis of combined experience and recommendation for management. A GCIG study. Gynecol Oncol. 2006; 100:233-238.
193. Pautier P, Ribrag V, Duvillard P, et al. Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type. Ann Oncol. 2007;18:1985-1989.
194. Nelsen LL, Muirhead DM, Bell MC. Ovarian small cell carcinoma, hypercalcemic type exhibiting a response to high-dose chemotherapy. S D Med. 2010;63(11):375-377.
195. Petru E, Pickel H, Heydarfadai M, et al. Non-genital cancers metastatic to the ovary. Gynecol Oncol. 1992;44:83-86.
196. Demopoulos RI, Touger L, Dubin N. Secondary ovarian carcinoma: A clinical and pathological evaluation. Int J Gynecol Pathol. 1987;6:166-175.
197. Young RH, Scully RE. Metastatic tumors in the ovary: A problem-oriented approach and review of the recent literature. Semin Diagn Pathol. 1991;8:250-276.
198. Moore RG, Chung M, Granai CO, et al. Incidence of metastasis to the ovaries from nongenital tract tumors. Gynecol Oncol. 2004;93:87-91.
199. Ayhan A, Tuncer ZS, Bukulmez O. Malignant tumors metastatic to the ovaries. J Surg Oncol. 1995;60:268-276.
200. Curtin JP, Barakat RR, Hoskins WJ. Ovarian disease in women with breast cancer. Obstet Gynecol. 1994;84:449-452.
201. Yada-Hashimoto N, Yamamoto T, Kamiura S, et al. Metastatic ovarian tumors: A review of 64 cases. Gynecol Oncol. 2003;89:314-317.
202. Ayhan A, Guvenal T, Salman MC, et al. The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries. Gynecol Oncol. 2005;98:235-241. [PubMed]
203. Khunamornpong S, Suprasert P, Chiangmai WN, et al. Metastatic tumors to the ovaries: A study of 170 cases in northern Thailand. Int J Gynecol Cancer. 2006;16(Suppl 1):132-138. [PubMed]
204. Antila R, Jalkanen J, Heikinheimo O. Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics. Gynecol Oncol. 2006;101:97-101. [PubMed]
205. Kim HK, Heo DS, Bang YJ, et al. Prognostic factors of Krukenberg's tumor. Gynecol Oncol. 2001;82:105-109.
206. Yakushiji M, Tazaki T, Nishimura H, et al. Krukenberg tumors of the ovary: A clinicopathologic analysis of 112 cases. Nihon Sanka Fujinka Gakkai Zasshi. 1987;39:479-485.
207. Misdraji J, Yantiss RK, Graeme-Cook FM, et al. Appendiceal mucinous neoplasms: A clinicopathologic analysis of 107 cases. Am J Surg Pathol. 2003;27:1089-1103.
208. Chou YY, Jeng YM, Kao HL, et al. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin. Histopathology. 2003;43:151-156.
209. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: Incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27:985-993.
210. Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: Gross and histologic findings in 50 cases. Am J Surg Pathol. 2003;27:281-292.
211. McBroom JW, Parker MF, Krivak TC, et al. Primary appendiceal malignancy mimicking advanced stage ovarian carcinoma: A case series. Gynecol Oncol. 2000;78:388-390.
212. Schofield A, Pitt J, Biring G, et al. Oophorectomy in primary colorectal cancer. Ann R Coll Surg Engl. 2001;83:81-84.
213. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008;26:5284-5293.
214. Ayhan A, Guvenal T, Coskun F, et al. Survival and prognostic factors in patients with synchronous ovarian and endometrial cancers and endometrial cancers metastatic to the ovaries. Eur J Gynaecol Oncol. 2003;24:171-174.
215. Young RH, Scully RE. Malignant melanoma metastatic to the ovary: A clinicopathologic analysis of 20 cases. Am J Surg Pathol. 1991;15:849-860.
216. Davis GL. Malignant melanoma arising in mature ovarian cystic teratoma (dermoid cyst): Report of two cases and literature analysis. Int J Gynecol Pathol. 1996;15:356-362.
217. Motoyama T, Katayama Y, Watanabe H, et al. Functioning ovarian carcinoids induce severe constipation. Cancer. 1991;70:513-518.
218. Robbins ML, Sunshine TJ. Metastatic carcinoid diagnosed at laparoscopic excision of pelvic endometriosis. J Am Assoc Gynecol Laparosc. 2000;7:251-253.
219. Fox H, Langley FA, Govan AD, et al. Malignant lymphoma presenting as an ovarian tumour: A clinicopathological analysis of 34 cases. BJOG. 1988;95:386-390.
220. Monterroso V, Jaffe ES, Merino MJ, et al. Malignant lymphomas involving the ovary: A clinicopathologic analysis of 39 cases. Am J Surg Pathol. 1993;17:154-170.
221. Azizoglu C, Altinok G, Uner A, et al. Ovarian lymphomas: A clinicopathological analysis of 10 cases. Arch Gynecol Obstet. 2001;265:91-93.
222. Sakurai N, Tateoka K, Taguchi J, et al. Primary precursor B-cell lymphoblastic lymphoma of the ovary: Case report and review of the literature. Int J Gynecol Pathol. 2008;27:412-417. [PubMed]